British Journal of Cancer

EDITORIAL BOARD

P.R. Twentyman  
D.G. Harnden  
P.J. Selby  

Editor  
Chairman  
Clinical editor

G.E. Adams  
P. Alexander  
K.D. Bagshawe  
M. Baum  
C.C. Bird  
N.M. Bleezen  
C.E.D. Chilvers  
T.A. Connors  
D. Crowther  
G.A. Currie  
J. Denekamp  
M.J. Embleton  
P. Gallimore  
C.F. Graham  
J.D. Hardcastle  
K.R. Harrap  
A.L. Harris  
H. Harris  
N. Hastie  
D. Heath  
J. Hickman  
A. Horwich  
A. Howell  
N.H. Kemp  
B. Ketterer  
L.J. Kinlen  
R.C.F. Leonard  
T.J. McElwain  
J.O'D. McGee  
J. Malpas  
C. Marshall  
N.A. Mitchison  
M. Moore  
A.M. Neville  
B. Ponder  
J. Pritchard  
T.J. Priestman  
J.G. Ratcliffe  
R.L. Souhami  
G.M. Taylor  
M.P. Vessey  
N.J. Wald  
P. Wardman  
R.A. Weiss  
G. Westbury  
N.M. Wilkie  
R.C.N. Williamson  
J.A. Wyke

Editorial Assistants

Janice Baiton (Cambridge)  
Julie Bingley (Sutton)
CLINICAL CANCER MONOGRAPHS:
THE OESOPHAGUS
H. R. Matthews, J. A. H. Waterhouse, J. Powell, C. C. McConkey, J. E. Robertson
Details the incidence of oesophageal cancer in the West Midlands Region of the UK over a period of 25 years.
The authors have analysed the results of different clinical treatments over the same 25-year period.
This is the first book to analyse such results over such a length of time.
June 1987 200pp
Hardback £48.00 0 333 42768 8

TOPICS IN NUCLEIC ACID STRUCTURE,
PART 3
Edited by Stephen Neidle
Following the good reception to Volumes 1 and 2, here is a further review volume on structural aspects of nucleic acid research. The papers report recent progress in various areas of DNA and RNA research, and give a good indication of further research possibilities.
September 1987 240pp
Hardback £42.50 0 333 33376 4

CANCER IN THE NECK
Edited by David L. Larsen, Alando J. Ballantyne and Oscar M. Guillamondeguí
Recent advances in the management of cancer in the neck have given way to increasingly sophisticated surgical, chemical, and radiotherapeutic techniques. In this important volume, internationally recognised authorities in all disciplines involved in the management of head and neck cancer provide a state-of-the-art reference on the appropriate treatment of various tumours that have metastasized to this region.
February 1987 304pp
Hardback £62.00 02.367760.0

METASTATIC SPREAD OF CANCER
G. V. Sherbet
A new approach to the analysis of the mechanisms of metastasis which compares the glioma, an intracranial tumour which ordinarily does not metastasise, to other metastasising tumour models. This produces a coherent picture of the operation of oncogenes and growth factors in the initiation, development and progression of neoplasms.
September 1987 228pp
Hardback £45.00 0 333 44362 4

ADVANCES IN UROLOGICAL ONCOLOGY
Volume 1 General Perspectives
Edited by Richard D. Williams, M.D.
This first volume in this new series includes comprehensive reviews of the most promising techniques in the diagnosis and treatment of cancers of the urinary tract.
The ten chapters cover oncogene expression and chromosome rearrangement, flow cytometry, tumour antigens, magnetic resonance and more.
July 1987 256pp
Hardback £35.00 02.427860.2

MOLECULAR GENETICS OF MAMMALIAN CELLS
Edited by George M. Malacinski, Christian C. Simonsen and Michael Shepherd
An international group of leading experts describe in detail the experimental approaches that can lead to a comprehensive and coherent view of the mechanisms that control mammalian embryogenesis and cell differentiation.
Highlighted throughout are potential practical applications of this research area, including the control of viral infections, gene therapy and production of industrial protein products through cell culture techniques.
April 1987 550pp
Hardback £45.00 02.947950.9

ORDER THESE BOOKS FROM YOUR LOCAL BOOKSELLER OR FROM: RICHARD GEDYE,
MACMILLAN PRESS LTD,
HOUNDMILLS,
BASINGSTOKE,
HANTS
RG21 2XS, UK.
TUMOUR MARKERS

RIGHT ON TARGET

MCA - A unique Breast Cancer Marker developed by Roche Diagnostics.

MCA has been shown to be extremely useful in follow-up studies and for post surgical monitoring.

The MCA kit is based on enzyme-immuno assay with all of the inherent advantages.

Other markers in the range of Roche enzyme-immuno assays are:

CA 125 - EIA <Roche>
For use in ovarian cancer.

CEA - EIA <Roche>
For use in many cancerous conditions such as carcinoma of the stomach, colon, pancreas etc.

AFP - EIA <Roche>
For both tumorous and non-tumorous conditions.

Roche Products Limited  Diagnostics Division  PO Box 8  Welwyn Garden City  Hertfordshire AL7 3AY  Telephone (0707) 328128
Aims and Scope

The British Journal of Cancer will accept papers which contain new information, constitute a distinct contribution to knowledge, and are relevant to the clinical, epidemiological, pathological or molecular aspects of oncology.

The Journal is published monthly on behalf of the Cancer Research Campaign by the Scientific and Medical Division, The Macmillan Press Ltd, Houndmills, Basingstoke, Hampshire RG21 2XS. Telephone: Basingstoke (0256) 29242.

Copyright © 1989 Cancer Research Campaign. ISSN 0007-0920.

Manuscripts plus two copies and all editorial correspondence should be sent to the Editor: Dr P.R. Twentyman, MRC Clinical Oncology and Radiotherapeutics Unit, Hills Road, Cambridge CB2 2QH, UK. Telephone: (0223) 210115

Annual subscription: UK £173; Rest of World £213 (or equivalent in any other currency). Orders must be accompanied by remittance. Cheques should be made payable to Macmillan Press and sent to: The Macmillan Press Ltd., PO Box 500, Leicester, LE99 0AA, UK. Where appropriate, subscribers may make payments into UK Post Office Giro Account No. 5192455. Full details must accompany the payment. Second class postage permit USPS 689-430.

Postmaster please send address corrections to British Journal of Cancer c/o Expediters of the Printed Word, Ltd., 515 Madison Avenue, New York, NY 10022, USA.

Enquiries concerning advertising space or rates should be addressed to: Advertising Department, British Journal of Cancer, Houndmills, Basingstoke, Hampshire RG21 2XS. Telephone: (0256) 29242. Fax: (0256) 479476

All rights of reproduction are reserved in respect of all papers, articles, illustrations, etc., published in this journal in all countries of the world.

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by The Macmillan Press Ltd for libraries and other users registered with the Copyright Clearance Centre (CCC) Transactional Reporting Service, provided that the base fee of $0.10 per copy, plus $0.10 per page is paid directly to CCC, 27 Congress St., Salem, MA 01970, USA. 0007-0920/88 $1.00+$0.10

Publisher: Harry Holt
Production & Editorial Services Manager: Nigel McNeil-Smith
Circulation Services: A.L. Clark
Promotion Manager: Richard Gedye

Cover illustration. TNF resistant variants of cell lines L929, U987 and RK13 have a different morphology, form more tightly packed colonies and adhere more strongly to plastic than the TNF sensitive parents. The resistant variants do not appear to communicate via gap junctions and no evidence was found for extracellular mediators of TNF resistance. See paper by Mathews and Neale, this issue (p. 189).

Whilst every effort is made by the publishers and editorial board to see that no inaccurate or misleading data, opinion or statement appears in this Journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Accordingly, the publishers and the editorial committee and their respective employees, officers and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement. Whilst every effort is made to ensure that drug doses and other quantities are presented accurately, readers are advised that new methods and techniques involving drug usage, and described within this Journal, should only be followed in conjunction with the drug manufacturer's own published literature.

Printed in Great Britain by Bell and Bain Ltd., Glasgow
Guest Editorial
Continuous, hyperfractionated, accelerated radiotherapy (CHART)
Dische, S. & Saunders, M.I.

Experimental Oncology
Enhanced therapeutic efficacy of 5′deoxy-5′fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolizing enzymes
Anticancer efficacy of 2-Chloroethyl nitrosourea derivatives of L-alanine, glycine, their di- and tripeptide homologues and the respective amidines in Methyl nitrosourea-induced rat mammary carcinoma
Klenner, T., Berger, M.R., Eisenbrand, G. & Schmahl, D.
Deficient activation by a human cell strain leads to mitomycin resistance under aerobic but not hypoxic conditions
Marshall, R.S., Paterson, M.C. & Rauth, A.M.
Enhanced anti proliferative action of busulphan by quercetin on the human leukaemia cell line K562
Hoffman, R., Graham, L. & Newlands, E.S.
The effect of hypobaric hypoxia on misonidazole binding in normal and tumour-bearing mice
MacManus, P., Maxwell, A.P., Abram, P. & Bridges, J.
Cytotoxin from polymorphonuclear leucocytes and inflammatory ascitic fluids
Yamazaki, M., Ikemura, M. & Sugiyama, T.
Human non-Hodgkin’s malignant lymphomas serially transplanted in nude mice conditioned with whole-body irradiation
Igarashi, T., Oka, K. & Miyamoto, T.
Chromosome 5 allele loss in familial and sporadic colorectal adenomas
Specific targeting and toxicity of sulfonated aluminium phthalocyanine photosensitised liposomes directed to cells by monoclonal antibody in vitro
Morgan, J., Gray, A.G. & Huehns, E.R.
Effect of diethylthiocarbamate on toxicity of doxorubicin, cyclophosphamide and cis-diaminedichloroplatinum(II) on mice hemopoietic progenitor cells
Pannaccìlli, I.M., Lenza, R.A., Bogliolo, G.V., Mencoboni, M.P. & Saviane, A.G.
Reducing the hypoxic fraction of a tumour model by growth in low glucose
Hlaky, L., Sachs, R.K. & Ring, C.S.
Potentiation of methotrexate lymphocytotoxicity in vitro by inhibitors of nucleoside transport
Hughes, J.M. & Tattersall, M.H.N.
The clonal origin of experimental large bowel tumours
Griffiths, D.F.R., Sacco, P., Williams, D., Williams, G.T. & Williams, E.D.

Clinical Oncology/Epidemiology
Clinical trials in cancer: The role of surrogate patients in defining what constitutes an ethically acceptable clinical experiment
The size of clinical trials in cancer research – what are the current needs?
Freedman, L.S.
Cell kinetics in acute lymphoblastic leukaemia: Comparative analysis between adults and children

Human hepatocellular cancers show a decreased prostaglandin E1 binding capacity
Virgolini, I., Sinzinger, H., Muller, C. & Herrmann, M.
An association between parameters of liver blood flow and percentage hepatic replacement with tumour
Alpha 1-microglobulin (HC protein) in human hepatocellular carcinoma
Vincent, C., Kew, M.C., Bouic, P., Flacher, M. & Revillard, J.P.
Alpha-l-fucosidase as a serum marker of hepatocellular carcinoma in Southern African blacks
Bukofzer, S., Stass, P.M., Kew, M.C., De Beer, M. & Groeneveld, H.T.
Predictors of hormone response for patients with ER unknown breast tumours
Hug, V., Thomas, H. & Bentzen, S.
Determination of estrogen receptors with monoclonal antibodies in fine needle aspirates of breast carcinoma
Marrazzo, A., La Bara, G., Taormina, P. & Bazan, P.
Squamous carcinoma of the oesophagus – histological criteria and their prognostic significance
The prophylactic role of intravenous and longterm oral acetylsalicylic acid after allogeneic bone marrow transplantation
Aetiology of oral cancer in patients less than or equal to 30 years of age
Sankaranarayanan, R., Mohideen, M.N., Nair, M.K. & Padmanabhan, T.K.

Prognostic factors in a T3 bladder cancer trial
Co-operative Urological Cancer Group
Endometrial cancer and patterns of use of estrogen replacement therapy: a cohort study
Long term risk of second malignant neoplasm after a cancer in childhood
De Vathaire, F., Schweisguth, O., Rodary, C., Francois, P., Sarrazin, D., Oberlin, O., Hill, C., Raquin, M.A., Dutreix, A. & Flamant, R.
Subsequent primary cancers in relation to treatment of ovarian cancer
Prior, P. & Pope, D.J.
Oral contraceptives and primary liver cancer
La Vecchia, C., Negri, E. & Parazzini, F.
Immunohistochemical localisation of tissue plasminogen activator in human brain tumours
Franks, A.J. & Ellis, E.
Arginine vasopressin – a mediator of chemotherapy induced emesis?
Edwards, C.M., Carmichael, J.J., Baylis, P.H. & Harris, A.L.

Phase 1 study of 21 days continuous infusion with vindesine
The prognostic value of a response to chemotherapy given before radiotherapy in advanced cancer of cervix
Geographical variation in mortality from leukaemia and other cancers in England and Wales in relation to proximity to nuclear installations, 1969–78
Human Cancer


G.C. KABAT and E.L. WYNDER: Type of alcoholic beverage and oral cancer.


THE WHO COLLABORATIVE STUDY OF NEOPLASIA AND STEROID CONTRACEPTIVES: Combined oral contraceptives and liver cancer.

J. BRANDSMA, B.R. LAUCER, P. PFISTER and M.H. SCHIFFMAN: Inter-laboratory variation as an explanation for varying prevalence estimates of human papillomavirus infection.

H. SUGIYAMA, T. HATTORI, S. FUHITA and M. FUKUDA: Distribution of fibronectin and laminin in early and advanced signet-ring-cell carcinomas of the stomach.


Experimental Cancer

S. TORSTEINDOTTIR, M.L. ANDERSSON, J. AVILA CARINO, B. EHILN-HENRIKSSON, M.G. MASUCCI, G. KLEIN and E. KLEIN: Reversion of tumorigenicity and decreased agarse clonability after EBV conversion of an IgH/myc translocation-carrying BL line.

P. PUCCETTI, R. BIANCHI, L. ROMANI, E. CENCI and M.C. FIORETTI: Delayed-type hypersensitivity to tumor antigens co-expressed with immunogenic determinants induced by xenogenization.


U. ZANGEMEISTER, K. THIEDE and V. SCHIRMER: Recruitment and activation of tumor-specific immune T cells in situ: functional studies using a sponge matrix model.


M.-T. DEARDEN-BADET, H. PELLETIER, A. CAIGNARD AND F. MARTIN: In vitro proliferative responses of spleen lymphocytes from rats bearing progressive or regressive tumors induced by cell variants of a syngeneic colon carcinoma.


Letter to the Editor

S. PEREYRA-ALFONSO AND E. BAL DE KIER JOFFE: Enhancement of urokinase-type plasminogen activator activity during the growth of a murine mammary adenocarcinoma.

Contents of the next issue.

Contents of other cancer journals.
Notice to Contributors

Manuscripts should be sent in triplicate (original plus two copies) to the Associate editor, Dr Peter Twentyman. The criteria for acceptance of manuscripts to be published in the British Journal of Cancer are originality and high scientific quality. Manuscripts are accepted on the understanding that they report unpublished work that is not under consideration for publication elsewhere, that all named authors have agreed to its submission and that if accepted it will not be published in the same form, in any language, without the consent of the Publishers. Papers should be in English. Authors whose mother-tongue is not English are urgently requested to have their manuscripts checked for linguistic correctness before submission.

Manuscripts should be typewritten, double-spaced with a wide margin and on one side of the paper only. They should be accompanied by a title page numbered as 1, bearing title, authors full names, affiliation and complete addresses, including postal (zip) codes; and a summary of not more than 200 words. The author and address to whom correspondence, proofs and reprint requests are to be sent should be clearly indicated.

Papers disregarding the welfare of experimental animals will be rejected.

Full papers should be divided into sections:
1. Introduction
2. Materials and methods
3. Results
4. Discussion
5. Acknowledgements and References.

Short Communications (~1500 words) should not have the above section headings nor a summary. The Editors reserve the right to make literary corrections.

Titles These are most important; authors should compose them with great care. They should combine brevity with clarity; the shorter the better, not exceeding 100 letters. Authors should submit their own running title, which must not exceed 50 letters.

References Only papers closely related to the author's work should be quoted, and these should be to original papers only. Exhaustive lists should be avoided. Citation of Conference Proceeding or Meetings Abstracts should also be avoided unless there is no other reference. References in the text should be made by giving the author's surname, with the year of publication in brackets. When the reference is to a specific part of a book, the page number should also be cited. When reference is made to a work by 3 or more authors, the first name followed by et al. should be used on all occasions. If several papers by the same first author and from the same year are cited, a, b, c, etc. should be added after the year of publication. It is the author's responsibility to check the accuracy of all references before submitting a manuscript. References should be brought together at the end of the paper in alphabetical order, where titles of papers and all authors' names should be given in full (except if there are more than 6 authors, when the first 3 names should be followed by 'and x others', x being the actual number). Names of journals should be abbreviated as in the Index Medicus, but with full stops after abbreviations (and after authors' initials), followed by the volume number and the page number, e.g.:


References to books and monographs should appear as in the following examples:


Abbreviations and units should follow the standards laid down in Units Symbols and Abbreviations published by the Royal Society of Medicine (third edition, 1977).

Figures In the text Arabic numbers should be used and all illustrations should be specifically referred to in the text, e.g. (Figure 2). All illustrations should be submitted at about 1½ times the intended final size and should be numbered as figures whether they are photographs, representational drawings or line diagrams and graphs.

Photographs and photomicrographs should be unmounted glossy prints, should not be retouched, and should be chosen to exclude technical artefacts. Magnification should be indicated by a line representing a defined length included within the photograph. Areas of key interest and/or critical reproduction should be indicated on a flimsy overlay attached to the photograph or on a photocopy. All annotation and lettering should be indicated in the same way, and preferably not included on the original print. Clearly contrasted and focussed prints are essential for adequate reproduction.

Line diagrams and graphs should be on separate sheets; they must be drawn with black Indian ink on white paper, of such originals. Lettering on figures should be minimal and must not duplicate the legend. The use of symbols should be consistent within papers, and explanation of symbols should be included in the caption, not on the figure.

A photocopy of all illustrations should be submitted.

Tables These should be as few as possible and should present only essential data. They should be typewritten on separate sheets, have a title or caption, and given Roman numbers.

Proofs Two marked copies of the proofs will be sent to the principal authors which should be read carefully for errors. One corrected copy must be returned to the Editor within 3 days. Major alterations to the text cannot be accepted.

Copyright Assignment The principal author must complete and return to the Publisher the Copyright Assignment Form enclosed with the proofs.

Offprints Twenty-five offprints will be supplied free of charge to the principal author. Additional offprints may be ordered on the form accompanying proofs. The charges are necessarily higher if orders are received after the issue has gone to press.

*Editorial correspondence should be addressed to the Editor, Dr P.R. Twentyman, MRC Clinical Oncology and Radiotherapeutics Unit, Hills Road, Cambridge CB2 2QH, UK.